Stock Analysis
- China
- /
- Life Sciences
- /
- SZSE:300759
Pharmaron Beijing First Quarter 2024 Earnings: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)
Pharmaron Beijing (SZSE:300759) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥2.67b (down 2.0% from 1Q 2023).
- Net income: CN¥230.6m (down 34% from 1Q 2023).
- Profit margin: 8.6% (down from 13% in 1Q 2023). The decrease in margin was primarily driven by higher expenses.
- EPS: CN¥0.13 (down from CN¥0.20 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pharmaron Beijing Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.
Performance of the Chinese Life Sciences industry.
The company's shares are up 5.4% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Pharmaron Beijing that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Pharmaron Beijing is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300759
Pharmaron Beijing
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally.
Undervalued with excellent balance sheet.